Carregant...
Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
BACKGROUND: The potential benefits and possible risks associated with combined nimotuzumab and concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma (NPC) have yet to be determined. METHODS: The databases PubMed, Web of Science, China National Knowledge Infrastructure, and...
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5694200/ https://ncbi.nlm.nih.gov/pubmed/29180878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141538 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|